Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cook Pharmica, a division of Cook Medical, has signed an agreement with Inspiration Biopharmaceuticals to conduct development work for its lead biologic therapy, an intravenous Factor IX product for patients with hemophilia B.
Subscribe to our email newsletter
Activities will be performed in Cook Pharmica’s development laboratory within its Bloomington facility. Terms of the agreement have not been released.
Jerry Arthur, president of Cook Pharmica, said: “We are very excited to join with Inspiration Biopharmaceuticals as their contract service provider and help bring this crucial therapy to patients. This is another significant milestone for Cook Pharmica and we look forward to partnering with this innovative company.”
Michael Griffith, president and CEO of Inspiration Biopharmaceuticals, said: “We are pleased to be working with Cook Pharmica. We look forward to our partnership as we prepare for large-scale manufacturing of our Factor IX product for the treatment of hemophilia B.”